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ABSTRAK 
 
Latar belakang dan objektif: Vascular Endothelial Growth Factor (VEGF) 
adalah faktor angiogenik yang memainkan peranan penting dalam 
pertumbuhan kanser seiring dengan penyelidikan yang berterusan mengenai 
peranannya sebagai faktor prognosis dan juga disasarkan sebagai agen 
terapeutik anti-angiogenik dalam kanser tiroid. VEGF diketahui memiliki hubung 
kaitdengan reseptor VEGF (VEGFR) seperti VEGFR-1 (Flt-1) dan VEGFR-2 
(KDR) dalam keadaan patologi seperti yang telah ditunjukkan dalam kajian 
sebelumnya. Kanser tiroid papilari (PTC) adalah kanser tiroid yang paling 
banyak ditemui dan kajian menunjukkan insiden kanser yang semakin 
meningkat dalam bengkak kelenjar tiroid (MNG). Tujuan kajian ini adalah untuk 
menentukan ekspresi VEGF dan VEGFR dalam bengkak kelenjar tiroid (MNG) 
dan kanser tiroid papilari (PTC). 
 
Bahan dan kaedah: Satu kajian keratan rentas ke atas 113 kes MNG dan 67 
kes PTC diambil dari arkib paraffin blok tisu dari tahun 2003 hingga ke 2014. 
Tisu sampel telah diposes dan dijalankan ujian immunohistokimia bagi 
menentukan ekspresi VEGF, VEGFR -1 dan VEGFR-2. Maklumat tentang 
kanser dalam kelenjar limfa and tisu di luar kelenjar tiroid juga diperolehi. 
 
Keputusan: Purata umur pesakit PTC adalah 44.7 ± 15.8 tahun dan MNG 
adalah 42.2 ± 13.6 tahun. Pesakit perempuan adalah majoriti bagi kedua-dua 
diagnosis dengan 86% (97/113) dalam MNG dan 78% (52/67) dalam PTC. 
Terdapat perbezaan statistik untuk ekspresi VEGFR-1 (p = 0.028) dan VEGFR-
xiv 
 
2 (p = 0.003) antara MNG dan PTC. Walau bagaimanapun, tiada perbezaan 
yang signifikan untuk ekspresi VEGF (p = 0.576) antara MNG dan PTC. 
Ekspresi bersama VEGF dan VEGFR-1 adalah penting dalam kedua-dua MNG 
(p = 0.016) dan PTC (p = 0.03), sementara itu tidak ada hubungan yang 
signifikan untuk ekspresi bersama VEGF dan VEGFR-2 (p> 0.05). Pesakit 
dibahagikan kepada kumpulan muda (<45 tahun) dan kumpulan umur yang 
lebih tua (≥45 tahun). Kebanyakan pesakit yang positif untuk metastasis 
kelenjar limfa dan kanser dalam tisu luar tiroid adalah wanita dan daripada 
kumpulan umur yang lebih tua. Dalam 15 kes PTC yang menunjukkan kanser 
dalam kelenjar limfa, 60% (9/15) adalah perempuan dan 53% (8/15) berumur 
45 tahun dan ke atas. Semua dua kes yang menunjukkan kanser dalam tisu 
luar tiroid terdiri daripada kumpulan umur yang lebih tua dan perempuan. Tidak 
ada hubungan yang signifikan (p> 0.05) antara status kelenjar limfa dan kanser 
dalam tisu luar tiroid dengan kumpulan umur, jantina, VEGF dan VEGFR. 
 
Kesimpulan: VEGF, VEGFR-1 dan VEGFR-2 menunjukkan ekspresi dalam 
kedua-dua MNG dan PTC. Ekspressi VEGFR-1 dan VEGFR-2 lebih penting 
dalam PTC dengan keputusan menunjukkan signifikan bagi ekspresi bersama 
VEGF dan VEGFR-1. 
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ABSTRACT 
Background and objective: Vascular endothelial growth factor (VEGF) is an 
angiogenic factor that plays important role in tumour growth with ongoing 
research regarding its role as a prognostic factor and also targeted anti-
angiogenic therapeutic agent in thyroid cancer. VEGF is known to have high 
affinity to VEGF receptors such as VEGFR-1 (Flt-1) and VEGFR-2 (KDR) and 
their co-expression in pathological condition had been demonstrated in previous 
studies. Papillary thyroid carcinoma (PTC) is the most common differentiated 
thyroid cancer and studies showed the increasing incidence of carcinoma 
arising in multinodular goitre (MNG). The aim of the current study to determine 
the expression of VEGF and VEGF receptors (VEGFR) in thyroid nodular 
hyperplasia and PTC. 
 
Materials and methods: We conducted a cross sectional study based on 
retrieved paraffinized archival tissue blocks of 113 nodular hyperplasia and 67 
PTC from the thyroidectomy specimens from the year of 2003 to 2014.The 
tissue sections were then stained by immunohistochemistry for VEGF, VEGFR-
1 and VEGFR-2. The lymph node involvement and extrathyroid extension also 
were determined.  
 
Results: The mean age of PTC patients was 44.7 ± 15.8years and nodular 
hyperplasia subjectswere42.2 ± 13.6years. Female gender predominate in both 
benign nodular hyperplasia and PTC with, 86% (97 out of 113) and 78% (52 out 
of67) respectively. There was a statistical difference of VEGFR-1 (p=0.028) and 
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VEGFR-2 (p=0.003) expression between nodular hyperplasia and PTC. 
However, no significant difference of VEGF expression (p=0.576) between both 
diseases. Co-expression of VEGF and VEGFR-1 was significant in both nodular 
hyperplasia (p=0.016) and papillary thyroid carcinoma (p=0.03), meanwhile no 
relevant relationship for VEGF and VEGFR-2 expression (p>0.05). The patients 
were further divided into young age group (<45 years old) and older age group 
(≥45 years old). Most of the subjects positive for lymph node metastasis and 
had extrathyroid extension were female and from older age group. From 15 
lymph nodes with metastasis, 60% (9/15) were female and 53% (8/15) from 
older age group. All two cases that showed extrathyroid extension were from 
older age group and female. However, there was no significant association 
(p>0.05) between lymph node status and extrathyroid extension with age 
groups, gender, VEGF and VEGFR expression. 
 
Conclusions: VEGF, VEGFR-1 and VEGFR-2 showed overexpression in both 
benign thyroid nodular hyperplasia and PTC. The expression of VEGFR-1 and 
VEGFR-2 more significant in PTC with relevant co-expression of VEGF and 
VEGFR-1. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Thyroid carcinoma 
 
Thyroid carcinoma is a relatively rare tumour, but it represents the most 
frequent form of cancer of the endocrine glands. It represents about 1% of all 
human malignancies and about 90% of all endocrine tumours. Papillary thyroid 
carcinoma (PTC) represents about 90% and follicular thyroid carcinoma the 
10% of differentiated thyroid carcinoma. The annual incidence of thyroid cancer 
has been reported to range between 1.2 and 2.6 cases per 100,000 in men and 
2.0-3.8 cases per 100,000 in women (Taccaliti et al., 2012). An estimated 
60,220 new cases of thyroid cancer are expected to be diagnosed in 2013 in 
the United States (US), with 3 in 4 cases occurring in women. The incidence 
rate of thyroid cancer has been increasing sharply since the mid-1990s, and it is 
the fastest increasing cancer in both men and women.  From 2005 to 2009, 
incidence rates increased by 5.6% per year in men and 7.0% per year in 
women.  
 
1.1.2 Classification. 
 
Table 1.1: Histological classification of thyroid tumours. 
Source : World Health Organization (WHO) Pathology and Genetics of 
Tumours of Endocrine Organs (DeLellis and Williams, 2004). 
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Papillary carcinoma 
Follicular carcinoma 
Poorly differentiated carcinoma 
Undifferentiated (anaplastic) carcinoma 
Squamous cell carcinoma 
Medullary carcinoma 
Sclerosing mucoepidermoid carcinoma with eosinophils 
Mucinous carcinoma 
Mucoepidermoid carcinoma 
Mixed medullary and follicular cell carcinoma 
Spindle cell tumour with thymus-like differentiation 
Carcinoma showing thymus-like differentiation 
 
The interest of this study is papillary thyroid carcinoma. Papillary thyroid 
carcinoma is the most common type of malignant thyroid tumour and there has 
been an increasing incidence of papillary thyroid carcinoma worldwide for the 
past few decades (Witmer et al., 2002). 
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1.1.3 Etiology of thyroid carcinoma 
 
Epidemiologically ascertained risk factors of thyroid cancer are ionising 
radiation, the presence of thyroid adenoma and multinodular goitre. 
Multinodular goitre (MNG) is defined as the palpation of multiple discrete 
nodules in the enlarged thyroid gland (Shrestha and Shrestha, 2014). 
Multinodularity of goitre should no longer be considered an indicator of probable 
benign disease (Anwar et al., 2011). In published reports, the incidence of 
carcinoma in multinodular goitre is reported with a percentage that varies from 
10% (Hanumanthappa et al., 2012), 13 % (Shrestha D and Shrestha S 
2014), 13.7 % (Gandolfi et al., 2004) to 14.4% (Anwar et al., 2011). 
 
In most studies, among the malignancies in multinodular goitre, papillary 
carcinoma was the most common followed by follicular carcinoma and 
anaplastic carcinoma(Anwar et al., 2011; Shrestha and Shrestha, 2014). 
These studies show the prevalence of cancer is significant in nodular goitres 
and these malignant tumours are usually of the papillary type. Endemic goitre is 
a major health concern in many parts of the world including Malaysia. Seven 
states in the country have been noted to have high incidence of goitre, including 
Kelantan (Ministry of Health, Malaysia, 1998). 
 
Apart from radiation exposure as an aetiological factor in the thyroid cancer, 
major advances have been made in the past decade in the understanding of the 
molecular mechanisms involved in the initiation and progression of thyroid 
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carcinoma. Genes thought to be involved in papillary and follicular carcinomas 
include the gsp, ret, trk, ras, met and p53 oncogenes. Activation of the ret 
protooncogene located on chromosome 10 is critical in the initiation of papillary 
and medullary carcinoma while the p53 and N-ras may be important for 
progression of well differentiated thyroid carcinomas (Yu et al., 2005). 
 
1.1.4 Treatment and prognosis 
 
Treatment of differentiated thyroid cancer ususally involves surgical resection of 
the tumour either total or near total thyroidectomy. In many cases, it is followed 
by radiotherapy or radioactive Iodine (131I) therapy (Lazarus and Obuobie, 
2000; Mazzaferri, 2006). Thyroid remnant ablation is defined as 131I therapy 
administered to destroy presumably normal residual thyroid tissue (Mazzaferri, 
2006). The measurement of serum thyroglobulin (Tg) is the most sensitive 
marker of persistent disease and is used routinely as tumour marker in the 
follow up of these patients. However, the serum Tg concentration is unreliable 
when a large thyroid remnant is present (Lazarus and Obuobie, 2000; 
Mazzaferri, 2006). Apart from thyroidectomy, modified neck dissection is 
usually advisable in the present of cervical lymph node metastases (Mazzaferri, 
2006). 
 
Tumour staging of thyroid carcinoma relies on age of patients, size of primary 
tumour, extrathyroidal spread, and regional and distant metastases. These 
criteria play an important role as prognostic factors.  The application of TNM 
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system in staging of thyroid carcinoma is endorsed by the American Joint 
Committee on Cancer (AJCC) and the Union for International Cancer Control 
(UICC). In the TNM system, each cancer is assigned a letter or number to 
describe the primary tumour (T), lymph node involvement (N), and metastases 
(M) WHO Pathology and Genetics of Tumours of Endocrine Organs 
(DeLellis and Williams, 2004). 
 
 
1.2 Angiogenesis 
Angiogenesis is the process of new blood vessels formation from pre-existing 
microvasculature, primarily venules. The process of growth and expansion of 
the vasculature occurs in response to injury, ischaemia and also involved in 
pathological conditions like tumour growth. Angiogenesis promote the tumour to 
increase in size beyond the constraints of the original blood supply. This is an 
important process in the growth and metastasis of many cancers (E.Johnson 
and Wilgus, 2012; Klein et al., 2001; Kumar et al., 2013). Typically, 
angiogenesis is required for tumours to grow beyond 1 to 2mm in size and 
offers a route for tumour cells to disseminate to secondary sites (Folkman, 
2002). For tumour development and progression, many researchers have been 
looking into apoptotic and angiogenic activities of cancer cells (Younes et al., 
2006).  Tumour cells are thought to secrete angiogenic factors to induce 
neovascularization around tumours (Katoh et al., 1999). 
 
 
6 
 
1.2.1 Vascular Endothelial Growth Factor (VEGF). 
 
Vascular endothelial growth factor (VEGF) is a potent pro-angiogenic factor 
which it has the ability to induce angiogenesis (Dvorak et al., 1995; E.Johnson 
and Wilgus, 2012). VEGF is also known as vascular permeability factor (VPF) 
and it is one of the vascular permeabilizing agent (Dvorak et al., 1995; Katoh 
et al., 1999). The accumulation of VEGF on the endothelium of tumour blood 
vessel has been associated with hyperpermeability of microvessels, primarily 
postcapillary venules and small veins for macromolecules (Dvorak et al., 1995; 
Katoh et al., 1999). 
 
1.2.2 VEGF Receptors (VEGFR) 
 
There are 3 types of vascular endothelial growth factor receptors (VEGFR) with 
high affinity to VEGF which are known as VEGFR-1 (Flt-1), VEGFR-2 (KDR in 
human and Flk-1 in mice) and VEGFR-3 (Flt-4, lymphatic endothelial cells). 
VEGFRs are members of a receptor tyrosine kinase family which localized 
endothelial cells during embryonic development. VEGFRs mediate signaling in 
endothelial cells of blood and lymph vessels, which induce cell proliferation, 
survival, or differentiation. This signaling is required for normal development 
and maintenance of the vascular bed and for angiogenic responses under 
(patho)physiological conditions (Witmer et al., 2002). 
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1.2.3 VEGF and targeted therapy 
 
Angiogenesis is of central importance in tumour growth and progression as it 
involves in sprouting of new vessels from existing blood vessels. As a result, 
tumour angiogenesis is a target of cancer therapy (Katoh et al., 1999; Kumar 
et al., 2013). The vascular endothelial growth factor (VEGF) family is involved in 
one of the steps in angiogenesis, which it increase permeability. Therefore 
VEGF is considered as a potential target for anti-angiogenic therapeutic 
strategies against cancer (Witmer et al., 2002). 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Incidence of malignancy in multinodular goitre. 
 
Multinodular goitre also termed nodular hyperplasia has been cited in the 
literature as an associated factor of thyroid cancer, particularly papillary 
carcinoma (Anwar et al., 2011; Gandolfi et al., 2004; Shrestha and Shrestha, 
2014). 
 
In the management of nodular goitre, the primary challenge is to rule out 
malignancy (Anwar et al., 2011). It may present either as a solitary nodule or 
as a dominant nodule in a multinodular goitre. Thyroidectomy is the choice of 
treatment in solitary or multiple nodules which produce pressure symptoms or 
become cosmetically unacceptable. Those nodules which are suspected of 
malignancy are similarly best treated by surgery (Anwar et al., 2011). 
 
Various studies have reported the incidence of malignancy in multinodular 
goitre. Anwar et al. (2011) in 204 cases of nodular goitres found a frequency of 
malignancy in 16.18% of their cases. The authors further divided the nodular 
goitres into two categories; (1) solitary thyroid nodule when there was a single 
nodule palpable in the gland on clinical examination and (2) multinodular goitre 
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when more than one nodule was detected on examination. The prevalence of 
malignancy was higher in solitary thyroid nodule (24.32%) compared to 
multinodular goitre (14.37%). This finding supports that solitary thyroid nodules 
have high a possibility of being malignant; however multinodular goitres also 
demonstrate the potential risk of malignancy. The distribution type of  tumour 
also shows different in both solitary thyroid nodule and multinodular goitre. 
Follicular carcinoma (15.2%) was the commonest malignancy encountered in 
solitary thyroid nodules and papillary carcinoma (48.5%) was more frequent in 
multinodular goitres. 
 
In a study reported in 1996, histological examination of 300 consecutive cases 
of multinodular goitre specimens seen at Hospital Universiti Sains Malaysia 
(USM), 34% of them had malignant transformation (Madhavan and Othman, 
1996). Hanumanthappa et al. (2012) studied 100 multinodular goitre cases 
and 10 (10%) cases contained malignant foci. Among them, papillary thyroid 
carcinoma (60%) was the most common type of malignancy. D. Shrestha et al. 
(2014) found the frequency of malignancy in the multinodular goitre was 13%. 
Among the malignancies, papillary carcinoma was the most common (84.61%) 
followed by follicular carcinoma and anaplastic carcinoma (Shrestha and 
Shrestha, 2014). 
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2.2 Prognostic factors in papillary thyroid carcinoma 
 
There are few prognostic markers that being used among researchers in their 
reported series of thyroid cancer such as age, tumour size, extrathyroidal 
extension, distant metastasis, lymph node metastasis, gender and multifocality 
of thyroid cancer (Shaha, 2006). 
 
Ito et al. (2011) investigated four prognostic factors of papillary thyroid 
carcinoma which are important for predicting a patient’s prognosis. The factors 
were tumour size more than 4cm (T), lymph node metastasis measuring 3cm 
(N), extrathyroid extension of primary tumours (Ex) and extranodal carcinoma 
extension (LN-Ex). All these factors were evaluated from preoperative 
assessment and also as the results of intraoperative findings.  In this study, they 
investigated the differences in the significance of these prognostic factors 
according to patient age and sex. They further dividing the subjects into four 
groups based on age and sex: (1) older women (age ≥ 55 years); (2) older men 
(age ≥ 55 years); (3) younger women (age < 55 years); and (4) younger men 
(age <55 years). They studied the association of patient’s groups and 
prognostic factors with local recurrence, distant recurrence and carcinoma 
death. They found that the significance of prognostic factors of papillary thyroid 
carcinoma varied according to patient sex and age. The findings might 
contribute not only to evaluating the prognosis but also to deciding therapeutic 
strategies for each patient. The prominent prognostic factor for local and distant 
recurrences in older patients (≥ 55 years old) was extrathyroid extension of 
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primary tumours (Ex). This will alarm the surgeon to perform a careful and 
extensive excision of the site of carcinoma extension and extensive lymph node 
dissection, especially for older patients with was extrathyroid extension of 
primary tumours (Ex). 
 
2.3 Expression of VEGF and it’s receptors in differentiated thyroid cancer 
and benign thyroid. 
 
2.3.1 Angiogenesis and role of VEGF and it’s receptors. 
Blood vessel formation is also known as angiogenesis or neovascularization. 
Angiogenesis occurs by mobilization of endothelial precursor cells (EPCs) from 
the bone marrow and from pre-existing vessels (Figure 2.1). In angiogenesis 
from pre-existing vessels, the extension and branching initiated by motility and 
proliferation of endothelial cells to form the capillary sprouts. The mechanisms 
include vasodilation and increased permeability of the existing vessels, 
degradation of extracellular matrix (ECM), and migration of endothelial cells. 
One of the major step is vasodilation in response to nitric oxide and VEGF-
induced increased permeability of the pre-existing vessel (Kumar et al., 
2010b). 
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Figure 2.1: Mechanism of angiogenesis from pre-existing vessel occurs mainly 
by growth factor-driven outgrowth of residual endothelium, sprouting of new 
vessels, and recruitment of pericytes to form new vessels. 
Source: Robbins & Cotrans: Pathologic Basis of Disease. Kumar et. al. 2013, 9th 
edition. 
   
Angiogenesis plays a pivotal role in the pathogenesis and growth of 
differentiated thyroid cancer. The relevance of tumour angiogenesis in thyroid 
tumour is shown by significant correlations between microvessel density and 
increasing size of primary tumour, intrathyroid tumour spread, and disease-free 
survival. The importance of  angiogenesis in tumour progression and metastasis 
is well-recognized and its potential role in prognosis and therapeutic application 
has led to many ongoing clinical researches (Younes et al., 2006). 
 
VEGF plays a crucial role as growth factor in adult tissues for vascular 
development and neovascularization in physiologic angiogenesis and 
pathological processes occurring in chronic inflammation, wound healing, 
tumours, and diabetic retinopathy (Cross et al., 2003; Kumar et al., 2010b). 
VEGF promotes angiogenesis, induces migration and proliferation of endothelial 
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cells, and increases vascular permeability (Durante et al., 2011; Kumar et al., 
2010b; Lennard et al., 2001). 
 
There are several growth factors contribute to angiogenesis include VEGF, 
Fibroblast growth factor (FGF) and Angiopoietins. The VEGF family of growth 
factors includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E and 
placental growth factor (PlGF) (Kumar et al., 2013). VEGF-A, the most 
prominent member of the VEGF family, is generally referred to as VEGF and is 
one of the key regulators of angiogenesis, including after injury and also the 
promotion of tumour progression and metastasis (Durante et al., 2011; Kumar 
et al., 2013). VEGF-B and PlGF are involved in vessel development in the 
embryo. Lymphangiogenesis and angiogenesis are stimulated by VEGF-C and 
VEGF-D. VEGFs are expressed in most adult tissues, with the highest 
expression in epithelial cells adjacent to fenestrated epithelium such as 
podocytes in the kidney and pigment epithelium in the retina (Kumar et al., 
2013). 
 
VEGF-A, the original VEGF, exists in four different isoforms (comprising 121, 
165, 189 and 206 amino acids in humans), which are generated by alternative 
splicing of a single pre-mRNA species. The region encoding VEGF-A 
spans,14kb and contains eight exons (Figure 2.2). The isoforms differ in their 
ability to bind to heparan sulphate and extracellular matrix (ECM) (Cross et al., 
2003). 
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Figure 2.2: Exon structure of the vascular endothelial growth factor VEGF-A 
mRNA splice variants. The gene encoding VEGF-A consists of eight exons that 
encode several different structural motifs. Alternative splicing of a single pre-
mRNA species produces at least four different VEGF-A isoforms that vary in total 
amino-acid number. In humans these correspond to VEGF-A121, VEGF-A165, 
VEGF-A189 and VEGF-A206, of which VEGF-A165 is the predominant form. 
Source : Cross et al., 2003 
 
 
Hypoxia is an important inducer and regulator of  VEGF expression (Cross et 
al., 2003; Kumar et al., 2013). VEGF expression is implicated in several 
diseases that are characterized by excess angiogenesis include cancer. Thus, 
most of the tumours that express VEGF, leading to vascularization of the 
tumour and expansion of the tumour mass(Cross et al., 2003). 
 
 
VEGF bind to a family of tyrosine kinase receptors (VEGFR-1, VEGFR-2, and 
VEGFR-3). VEGF-A is generally binds to VEGFR-1, VEGFR-2 and VEGFR-3. 
VEGF-B and PlGF bind only to VEGFR-1; meanwhile VEGF-C and VEGF-D are 
expressed as propeptides that primarily bind to VEGFR-3 (Cross et al., 2003). 
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In pathological conditions, VEGF activity accommpany the increased levels of 
VEGF receptors expression including VEGFR-1, VEGFR-2, and VEGFR-3 
(Witmer et al., 2002). Of the various receptors for VEGF, VEGFR-2 is the most 
important in angiogenesis. It is expressed by endothelial cells and their 
precursors, by other cell types, and by many tumour cells (Cross et al., 2003; 
Jalali Nadoushan et al., 2012; Kumar et al., 2010b; Witmer et al., 2002). 
 
There are two high-affinity VPF/VEGF receptors have been described in 
vascular endothelium that are Flt-1 (VEGFR-1) and KDR (VEGFR-2). Both are 
transmembrane protein with cytoplasmic tyrosine kinase domains (Sherma, 
2003). At the sites of VPF/VEGF overexpression, both Flt-1 and KDR are 
commonly and strikingly overexpressed in adjacent microvascular endothelial 
cells. Examples include various human and animal tumours (Sherma, 2003). 
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Figure 2.3: Schematic illustration of vascular endothelial growth factor receptors 
(VEGFR) expression pattern and ligand specificity. 
Source: Cross et al., 2003 
 
VEGF is an angiogenic factor and its expression has been demonstrated in 
thyroid tissue. 
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Soh et al. (1997) conducted a study to look for expression of VEGF messenger 
RNA (mRNA) and production of VEGF protein in cell lines from human follicular 
carcinoma, papillary carcinoma, medullary thyroid carcinoma, Hurthle cell 
cancers, follicular adenoma and Graves’ thyroid tissue. They found that normal, 
hyperplastic, and neoplastic thyroid tissues all were expressing VEGF mRNA, 
and also secreting VEGF protein. However, the expression of VEGF mRNA was 
higher and the intensity of VEGF stain was stronger in thyroid cancer cells than 
normal thyroid cells.  In comparison between follicular tumour cell origin and 
parafollicular tumour cell origin, the results showed higher VEGF mRNA 
expression and stronger intensity of VEGF stain in the follicular tumour cells. 
The higher levels of VEGF expression in differentiated thyroid cancers of 
follicular cell origin suggests a role in oncogenesis. 
 
Vieira et al. (2005) conducted a study to look for expression of VEGF and 
VEGF receptors (VEGFR) in thyroid carcinomas of follicular origin as well as 
their role in thyroid carcinogenesis. They demonstrated that VEGF, VEGFR-1 
and VEGFR-2 were more expressed in papillary thyroid carcinoma compared to 
follicular thyroid carcinoma and poorly differentiated thyroid carcinoma. The 
expression of VEGF was significantly (p<0.05) more prevalent in papillary 
thyroid carcinoma (79%) compared to follicular thyroid carcinoma and poorly 
differentiated thyroid carcinoma. They also found higher expression of VEGFR-
1 and VEGFR-2 in papillary thyroid carcinoma with 76% and 68% of cases, 
respectively. Their study showed the correlation between VEGF expression and 
microvessel density was statistically significant in papillary thyroid carcinoma, 
but not in follicular thyroid carcinoma. 
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2.3.2 Difference of VEGF and it’s receptors expression in thyroid nodular 
hyperplasia and papillary thyroid carcinoma. 
 
Jebreel et al. (2007) found that VEGF was co-expressed with its receptors, 
VEGFR-1 and VEGFR-2, in both benign and malignant thyroid disease. In the 
study, the specimens are comprising of normal thyroid tissue, multinodular 
goitre, Grave’s disease, Hashimoto’s thyroiditis, follicular adenoma and papillary 
thyroid carcinoma with 92% of all thyroid tissue studied were positive for VEGF 
staining. There was an increase in both the distribution and intensity of VEGF 
staining in multinodular goitre, follicular adenomas and papillary carcinoma. 
They studied 7 cases of papillary thyroid carcinoma and 17 cases of 
multinodular goitre. For papillary thyroid carcinoma, they showed that 100% 
were positive for VEGF expression, 86% were positive for VEGFR-1 expression 
and 100% were positive for VEGFR-2 expression.  In multinodular goitre, there 
were 94% positive for VEGF expression, 94% were positive for VEGFR-1 
expression and 100% were positive for VEGFR-2 expression. Their findings 
also showed that VEGFR-1 and VEGFR-2 were widely expressed in the 
thyrocytes of both benign and neoplastic thyroid diseases; however the 
receptors showed minimal variation in co-expression with VEGF in the vascular 
endothelium. This suggesting that the up-regulation of VEGF and not its 
receptors occurs as tissue becomes autonomous. 
 
In a study performed by Katoh et al. (1999), 25 out of 28 thyroid tumour tissues 
were positive for VEGF including 9 out of 10 papillary thyroid carcinomas. They 
reported that the expression of both VEGF mRNA and VEGF protein 
immunohistochemically were identical in cells covering papillary areas. The 
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intensity of staining is more than that in the follicle-forming cell. These findings 
suggest the relation of VEGF and morphogenesis of papillae of papillary thyroid 
carcinoma. Focal endothelial staining was also noted in normal and neoplastic 
thyroid tissue. 
 
 
2.3.3 Expression of VEGF and it’s receptors in papillary thyroid carcinoma 
associated with prognostic factors. 
 
Jiang et al. (2005) studied 115 cases of papillary thyroid carcinoma and 20 
cases of nodular goitre. They reported that VEGF expression was significantly 
higher in papillary thyroid carcinoma (PTC) than in nodular goitre and closely 
related to the size of papillary thyroid carcinoma.  They also found VEGF-C and 
VEGF-D are closely related to lymph node metastasis of papillary thyroid 
carcinoma.  
 
Jalali Nadoushan et al. (2012) studied 99 cases of papillary thyroid carcinoma 
(PTC). They showed that 40.2% were positive for VEGFR expression. They 
concluded that there was no meaningful relationship between VEGFR 
expression and tumour size and gender of patients, but this relationship was 
seen between the expression of VEGFR and lymph nodes involvement.   
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In a study conducted by Lennard et al. (2001), they correlate the VEGF 
expression with the survival in papillary thyroid carcinoma. They studied 96 
subjects of papillary thyroid carcinoma with 98% show predominantly of slight-
to-moderate intensity of VEGF expression in the majority of the malignant cells. 
The pattern of VEGF staining in the initial surgical specimen is strongly 
associated with the incidence of local and distant metastasis in papillary thyroid 
carcinoma. These findings support that the intensity of VEGF expression is 
associated with increased risk of recurrence and decreased disease-free 
survival in papillary thyroid carcinoma. 
 
An increased in VEGF expression has been proposed as the prognostic marker 
in differentiated thyroid cancers; specifically papillary thyroid carcinoma in the 
study conducted by Jalali Nadoushan et al. (2012). An aggressive disease 
could have an increased VEGF production which indicates the ability of the 
tumour to metastasize. The final score of VEGF immunostaining was obtained 
by the multiplication of intensity score and proportion score (percentage of 
positivity). From the discriminant analysis, a value of 6 or more indicates that 
the tumours are at high risk of metastasis. This information can guide the 
physician for proper and close follow up schedule in the management of the 
patient. 
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2.4 Targeted therapy on VEGFR. 
 
Tyrosine kinase inhibitor is one of the interest researches in the targeted 
therapy in advanced thyroid cancer. 
Vieira et al. (2005) had concluded that VEGF autocrine action in thyroid 
carcinoma could play a crucial role in tumour cell survival and could represent a 
useful therapeutic target for thyroid tumours. They found that the blockade of 
either VEGF or its receptors with neutralizing antibodies significantly reduced 
cell viability (live/dead ratio) by 40% to 60%, increased apoptosis and delay in 
cell-cycle progression (increased in modest arrest of cells in in G0+G1 phase 
and decrease of cells in G2 phase) of the VEGFR-positive thyroid tumour cell 
line NPA’87. 
 
Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth 
factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. 
Axitinib was selected as the interest drug in the study by Cohen et al. (2008). 
Their objective was to assess the activity and safety of axitinib. They conducted 
a study on patients with advanced thyroid cancer of any histology with the most 
common type was papillary carcinoma, accounting for 30 (50%) of 60 cancers. 
The inclusive criteria was patients that resistant or not appropriate for 131I 
(iodine) treatment.  
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The primary assessment in their study was objective response rate (ORR) by 
Response Evaluation Criteria in Solid Tumours (RECIST). They demonstrated 
the results with the high response rate, prolonged duration of response, and 
overall survival. Most patients experienced some tumour shrinkage during 
axitinib treatment, with 5 out of 9 patients who treated with prior chemotherapy 
showed partial response and maximum tumour regression range of 36% to 
54%. Moreover, 38% of patients experienced stable disease for 16 weeks or 
more by RECIST, and the median progression-free survival time in excess of 18 
months. These results are notable given that majority of patients were men and 
had metastatic disease, which are risk factors for poor prognosis. 
 
Furthermore, they also demonstrated that axitinib is an oral inhibitor targeting 
VEGFRs. They investigated the effect of the drug on soluble proteins as 
exploratory pharmacodynamics markers. Axitinib was selectively decreased 
sVEGFR-2 and sVEGFR-3 plasma concentrations versus sKIT (stem-cell factor 
receptor). Cohen et al. (2008) concluded that axitinib has generally favourable 
safety profile and is a selective inhibitor of VEGFR with antitumour activity in all 
histologic subtypes of advanced thyroid cancer and also in patient with limited 
therapeutic options. 
 
(Younes et al. (2006)) reported that simultaneous blockade of Epidermal 
growth factor receptor (EGFR) and Vascular endothelial growth factor receptor 
(VEGFR) signalling by AEE788 alone or in combination with paclitaxel can 
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significantly reduce follicular thyroid carcinoma tumour volume in nude mice by 
both direct antitumor and antiangiogenic effects. 
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CHAPTER 3 
 
AIMS AND OBJECTIVES 
 
3.1 Rational of the study 
 
Papillary thyroid carcinoma is the most common type of thyroid malignancy, 
which represents 90% of differentiated thyroid carcinoma with excellent overall 
survival, with a 10-year survival rate in excess of 95% (Kumar et al., 2010a; 
Taccaliti et al., 2012). VEGF is participating in the induction and progression of 
neoplastic process involving the thyroid gland, by playing a key role in 
vascularization of solid tumours (Konturek and Barczynski, 2012). Increased 
VEGF expression has been associated with poor clinical outcomes in many 
malignancies. Several recent reports documented over expression of VEGF in 
papillary thyroid carcinoma (Lennard et al., 2001). Overexpression of VEGF 
and it’s receptors could guide the physician in close and proper follow up of the 
patient. By understanding the underlying process of angiogenesis, it has been a 
promising therapeutic target to inhibit tumour angiogenesis (E.Johnson and 
Wilgus, 2012; Kumar et al., 2013). 
 
 
 
 
 
 
